Andrew Baldi

Andrew Baldi

Auto-generated profile, based on publicly available information

Andrew Baldi

Population Health and Immunity Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Australia

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 October 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
ABAndrew Baldi
Andrew Baldi
SBSabine Braat
Sabine Braat
MHMohammed Imrul Hasan
Mohammed Imrul Hasan
CBCavan Bennett
Cavan Bennett
MBMarilou Barrios
Marilou Barrios
SPSant-Rayn Pasricha
Sant-Rayn Pasricha
Anemia is highly prevalent globally, especially in young children in low-income countries, where it often overlaps with a high burden of diarrheal disease. Distribution of iron interventions (as supplements or iron-containing multiple micronutrient powders, MNPs) is a key anemia reduction strategy. Small studies in Africa indicate iron may reprofile the gut microbiome towards pathogenic species. We seek to evaluate the safety of iron and MNPs based on their effects on diversity, composition, and function of the gut microbiome in children in rural Bangladesh as part of a large placebo-controlled randomized controlled trial of iron or MNPs given for 3 months (ACTRN12617000660381). In 923 infants, we evaluate the microbiome before, immediately following, and nine months after interventions, using 16S rRNA gene sequencing and shotgun metagenomics in a subset. We identify no increase in diarrhea with either treatment. In our primary analysis, neither iron nor MNPs alter gut microbiome diversity or composition. However, when not adjusting for multiple comparisons, compared to placebo, children receiving iron and MNPs exhibit reductions in commensal species (e.g., Bifidobacterium, Lactobacillus) and increases in potential pathogens, including Clostridium. These increases are most evident in children with baseline iron repletion and are further supported by trend-based statistical analyses.

16 March 2023 in Blood
Verified
Journal Article
Open access
PDF file
CBCavan Bennett
Cavan Bennett
VJVictoria E Jackson
Victoria E Jackson
APAnne Pettikiriarachchi
Anne Pettikiriarachchi
THThomas Hayman
Thomas Hayman
USUte Schaeper
Ute Schaeper
SPSant-Rayn Pasricha
Sant-Rayn Pasricha
Polycythemia Vera (PV) is a myeloproliferative neoplasm driven by activating mutations in JAK2 that result in unrestrained erythrocyte production, increasing patients' hematocrit and hemoglobin concentration, placing them at risk of life-threatening thrombotic events. Our GWAS of 440 PV cases and 403,351 controls utilizing UK Biobank data found that SNPs in HFE known to cause hemochromatosis are highly associated with PV diagnosis, linking iron regulation to PV. Analysis of the FinnGen dataset independently confirmed over-representation of homozygous HFE variants in PV patients. HFE influences the expression of hepcidin, the master regulator of systemic iron homeostasis. Through genetic dissection of PV mouse models, we show that the PV erythroid phenotype is directly linked to hepcidin expression: endogenous hepcidin upregulation alleviates erythroid disease whereas hepcidin ablation worsens it. Further, we demonstrate that in PV, hepcidin is not regulated by expanded erythropoiesis but is likely governed by inflammatory cytokines signaling via GP130 coupled receptors. These findings have important implications for understanding the pathophysiology of PV and offer new therapeutic strategies for this disease.

14 August 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
ABAndrew Baldi
Andrew Baldi
SBSabine Braat
Sabine Braat
MHMohammed Imrul Hasan
Mohammed Imrul Hasan
CBCavan Bennett
Cavan Bennett
MBMarilou Barrios
Marilou Barrios
SPSant-Rayn Pasricha
Sant-Rayn Pasricha
Antibiotics may alter the gut microbiome, and this is one of the mechanisms by which antimicrobial resistance may be promoted. Suboptimal antimicrobial stewardship in Asia has been linked to antimicrobial resistance. We aim to examine the relationship between oral antibiotic use and composition and antimicrobial resistance in the gut microbiome in 1093 Bangladeshi infants. We leverage a trial of 8-month-old infants in rural Bangladesh: 61% of children were cumulatively exposed to antibiotics (most commonly cephalosporins and macrolides) over the 12-month study period, including 47% in the first 3 months of the study, usually for fever or respiratory infection. 16S rRNA amplicon sequencing in 11-month-old infants reveals that alpha diversity of the intestinal microbiome is reduced in children who received antibiotics within the previous 7 days; these samples also exhibit enrichment for Enterococcus and Escherichia/Shigella genera. No effect is seen in children who received antibiotics earlier. Using shotgun metagenomics, overall abundance of antimicrobial resistance genes declines over time. Enrichment for an Enterococcus-related antimicrobial resistance gene is observed in children receiving antibiotics within the previous 7 days, but not earlier. Presence of antimicrobial resistance genes is correlated to microbiome composition. In Bangladeshi children, community use of antibiotics transiently reprofiles the gut microbiome.

27 February 2026 in Science Advances
Verified
Journal Article
Open access
DCDanielle Clucas
Danielle Clucas
CBCavan Bennett
Cavan Bennett
RHRebecca Harding
Rebecca Harding
APAnne Pettikiriarachchi
Anne Pettikiriarachchi
ABAndrew Baldi
Andrew Baldi
RARicardo Ataide
Ricardo Ataide
Iron deficiency, anemia, and Plasmodium infection are global health challenges with overlapping geographical distributions, particularly affecting pregnant women in Africa, yet the mechanisms underlying their interactions remain poorly understood. We used a multilayered approach combining clinical data from Malawian pregnant women ( n = 711) in the REVAMP trial, a genetic mouse model [ Tmprss6 -knockout (KO)], and in vitro Plasmodium falciparum cultures to clarify iron-malaria associations. Iron deficiency was associated with 50% reduced P. falciparum parasitemia in pregnant women [95% CI (30 to 64%), P < 0.0001], while iron-deficient mice exhibited improved survival against P. berghei (median 15.5 days versus 7.0 days for WT mice) and protection from cerebral malaria (83% versus 17% survival). Iron chelation substantially changed the transcriptomic and proteomic profile of cultured P. falciparum parasites. Intravenous iron supplementation did not increase parasitemia when coupled with malaria prevention. These findings demonstrate that iron deficiency protects against Plasmodium infection and support World Health Organization recommendations for iron supplementation in malaria-endemic regions when combined with adequate malaria prevention strategies in place.

15 November 2022 in Blood
Verified
Journal Article
Open access
ABAndrew J Baldi
Andrew J Baldi
SPSant-Rayn Pasricha
Sant-Rayn Pasricha
AJAaron R Jex
Aaron R Jex
MHM Imrul Hasan
M Imrul Hasan
NJNaomi Jones
Naomi Jones
RBRory Bowden
Rory Bowden
Children in low- and middle-income countries (LMICs) have a high burden of anemia, much of which is attributable to iron deficiency. The World Health Organizati

19 February 2025 in The American Journal of Clinical Nutrition
Verified
Journal Article
Open access
LLLeila Larson
Leila Larson
ABAndrew Baldi
Andrew Baldi
MHMohammed Imrul Hasan
Mohammed Imrul Hasan
NJNaomi Jones
Naomi Jones
EPEmily Owens Pickle
Emily Owens Pickle
SBSabine Braat
Sabine Braat
Hepcidin can determine individuals' responses to iron supplementation, but limited evidence exists from pediatric trials. We aimed to examine the influence of hepcidin on the effects of supplementation with iron syrup and multiple micronutrient powders (MNPs) on hemoglobin and ferritin concentrations and incidence of diarrhea in young children. Participants included a subsample of 1281 8-month-old children enrolled in a three-arm, double-blind, double-dummy, individually randomized controlled trial examining the efficacy of 3 months of universal supplementation with daily iron syrup (12.5mg iron), MNPs (containing 12.5mg iron), or placebo in children living in Bangladesh. In all participants at baseline, immediately post-intervention (month 3), and after a further 9 months of follow-up (month 12), serum hepcidin concentrations were measured by ELISA, venous hemoglobin by HemoCue® 301, and incidence of diarrhea by caregiver report. We used a likelihood-based longitudinal data analysis model to examine effect modification from baseline hepcidin on effects of iron syrup or MNPs on hemoglobin and ferritin concentrations and log-binomial model on incidence of diarrhea at months 3 and 12. Hepcidin modified the effect of MNPs, but not iron syrup, compared to placebo on hemoglobin and ferritin concentrations immediately post intervention. The treatment effect of MNPs compared to placebo in the change from baseline to month 3 was larger among children with low compared to not-low baseline hepcidin (hemoglobin: mean difference 11.6g/L (7.2, 15.9) compared to 4.3 (3.09, 5.7), p-interaction=0.002; ferritin: geometric mean ratio 2.4 (1.6, 3.6) compared to 1.5 (1.3, 1.7), p-interaction=0.024). This effect modification was not sustained at month 12. Hepcidin did not modify effects of either intervention on incidence of diarrhea. Immediate effects of MNPs on child hemoglobin and iron status are larger among those with low compared to not-low hepcidin, indicating that pre-intervention screening could help identify those who would benefit most from MNPs. ACTRN12617000660381.